AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03839043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief behavioral intervention
Description: Quit for a bit- \*advice to quit from the am. of surgery until one week post-surgery, a special emphasis on morning abstinence\* risks of smoking to perioperative outcomes, includes wound infections, breathing problems, and heart problems\*reduction of these risks if able to quit for a bit\*the fact that most smokers don't experience cravings or increased stress around the time of surgery. Subjects will receive written summarizing instructions and a brief abstinence brochure. Quit for good- 3 out of the 5A's smoking cessation intervention, including Asking, Advising and Assistance will be provided. The advice endorses immediate, sustained quitting (quit for good), accent on the health and economic benefits of long-term abstinence. Assistance includes a method of setting the date of surgery as the quit date, enlisting social support, anticipation of withdrawal symptoms, and the need for complete abstinence. Subjects will receive written summarizing instructions and a 5As brochure.
Study NCT03839043 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief behavioral intervention
Description: Quit for a bit- \*advice to quit from the am. of surgery until one week post-surgery, a special emphasis on morning abstinence\* risks of smoking to perioperative outcomes, includes wound infections, breathing problems, and heart problems\*reduction of these risks if able to quit for a bit\*the fact that most smokers don't experience cravings or increased stress around the time of surgery. Subjects will receive written summarizing instructions and a brief abstinence brochure. Quit for good- 3 out of the 5A's smoking cessation intervention, including Asking, Advising and Assistance will be provided. The advice endorses immediate, sustained quitting (quit for good), accent on the health and economic benefits of long-term abstinence. Assistance includes a method of setting the date of surgery as the quit date, enlisting social support, anticipation of withdrawal symptoms, and the need for complete abstinence. Subjects will receive written summarizing instructions and a 5As brochure.
Study NCT03839043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS Program
Description: Quit for a bit- Subjects will get SMS messages focused on maintaining abstinence from the morning of surgery until one week after surgery. SMS content focus on the benefits of abstinence to surgical recovery rather than sustained benefits to overall health. Around day 7 postoperatively, messages will encourage subjects to consider extending their abstinence beyond 7 days.Quit for good- Subjects will get SMS messages focused on general advice for maintaining abstinence, focusing on the long-term health benefits rather immediate benefits to recovery from surgery. SMS content focus on the the surgical date as the quit date, general advice and support for quitting based on the standard Truth Initiative (UbiQUITxt) message library and there will be no references to effects of short-term abstinence on surgical outcomes.
Study NCT03839043 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMS Program
Description: Quit for a bit- Subjects will get SMS messages focused on maintaining abstinence from the morning of surgery until one week after surgery. SMS content focus on the benefits of abstinence to surgical recovery rather than sustained benefits to overall health. Around day 7 postoperatively, messages will encourage subjects to consider extending their abstinence beyond 7 days.Quit for good- Subjects will get SMS messages focused on general advice for maintaining abstinence, focusing on the long-term health benefits rather immediate benefits to recovery from surgery. SMS content focus on the the surgical date as the quit date, general advice and support for quitting based on the standard Truth Initiative (UbiQUITxt) message library and there will be no references to effects of short-term abstinence on surgical outcomes.
Study NCT05365945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NDT Bobath therapy
Description: Their physiotherapy was based on exercises that heavily employed the core muscles to equalize tension and strength, according to the NDT Bobath concept. The duration of the treatment session for each patient in both groups was 120 minutes.
Study NCT05365945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The classic exercises.
Description: They underwent classical neurological rehabilitation. such as passive exercises, but also an approximation. In addition, the patients performed self-assisted exercises on a manual rotor, and in order to relieve the directly affected limb, the patients exercised in a suspension system. As the physiotherapy progressed, the patients performed active exercises, and then active exercises with resistance, e.g. using the Thera Band. Patients also exercised their balance with the use of large gymnastic balls or sensor pads. A large part of the physiotherapy was locomotion training and gait re-education.~The duration of the treatment session for each patient in both groups was 120 minutes.
Study NCT03982862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 0.1ml 2% Xylocaine
Study NCT03982862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Description: 4U Botox® diluted to 0.1 ml
Study NCT02776202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine monophosphate
Description: The HSCT preparative regimen will consist of~* Thymoglobulin: 2.5 mg /kg/day intravenously (IV) on Days -8 through -5~* Fludarabine: 35 mg/m2/day IV on Days -8 through -4~* Melphalan: 140 mg/m2 IV on Day -3~* Rest on Day -2 and -1~* Day 0 is the day of transplant~* GVHD prophylaxis: sirolimus beginning on Day -1 for at least one year and mycophenolate mofetil (MMF) from Day -3 to +45 or to 7 days after neutrophil engraftment, whichever is later.
Study NCT04008927 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HCV screening
Description: All patients will have HCV screening using rapid tests. HIV and HBV testing will also be conducted and patients will be appropriately referred to appropriate health services.
Study NCT04008927 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnosis of hepatitis C
Description: HCV-RNA assay (GeneXpert, Cepheid) will be performed for all participants with positive HCV serology to determine if patients have chronic hepatitis C (defined by HCV-RNA>10 UI/mL). In addition a measure of the liver stiffness will be performed.
Study NCT04008927 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: HCV treatment
Description: Direct-Acting Antiviral drugs will be prescribed for 8 or 12 weeks according to liver assessment.
Study NCT04803682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventive Intervention
Description: Participate in ASPIRE and mentorship program
Study NCT04803682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies (pre and post questionnaire)
Study NCT03815578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical examination
Description: * Number of painful joints,~* Number of swollen joints,~* Patient Global assessment VAS (0 - 100)~* and Physician Global assessment VAS (0 - 100)
Study NCT03815578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain assessment
Description: * Pressure Pain Thresholds (PPTs),~* Mechanical Temporal Summation (MTS)~* and Diffuse Noxious Inhibitory Control (DNIC)
Study NCT03815578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 18 ml whole blood for ELISA analysis and miRNAs detection
Study NCT03815578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Reported Outcomes
Description: * Health Assessment Questionnaire (HAQ),~* Rheumatoid Arthritis Impact of Disease score (RAID),~* Daily joint pain intensity VAS (0-100),~* Hospital Anxiety and Depression scale~* and Coping Strategy Questionnaire.
Study NCT04416230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: massage
Description: The massage included 30 minutes of gentle friction, kneading, stroking, and passive touch on the infant's accessible upper extremities, lower extremities, head, face, and back.
Study NCT00934102 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Narafilcon A contact lens
Description: Investigational, silicone hydrogel, spherical soft contact lens
Study NCT03430076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: revascularization
Description: open revascularization for below-knee popliteal in the absence of an suitable autologous vein with PTFE.
Study NCT03430076 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: revascularization
Description: open revascularization for below-knee popliteal in the absence of an suitable autologous vein with PTFE.
Study NCT03430076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Propaten®
Description: Propaten®
Study NCT03430076 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crude PTFE
Description: Crude PTFE
Study NCT00948467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-733
Description: The Initial Escalation Stage will enroll approximately 30 patients with advanced nonhematologic malignancies. TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days.~The Expansion Stage will enroll approximately 30 patients with advanced metastatic melanoma. The recommended phase 2 dose determined in the Initial Escalation Stage of TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days.
Study NCT02073383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary brachial plexus block
Study NCT02073383 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary brachial plexus block
Study NCT05694377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electroencephalography-based neurofeedback (EEG-NFB)
Description: The EEG-NFB training program will involve nine training sessions (three times a week over a 3-week period) each lasting 30 min. EEG-NFB training will be conducted with ProComp Infiniti Encoder and BioGraph Infiniti Software v.5.1.3. The training protocol will be set to decrease the EEG TBR value. For the 12 training sessions, all participants will be subjected the same EEG-NFB protocol at C3 electrode. The EEG-NFB training sessions consists of a 20-s baseline period (i.e., with no feedback), 30-min feedback presentation, and another 20-s baseline period. Subjects will be seated in front of a computer screen and animations will be used as feedback; the animation starts when the subject is sufficiently focused for 20 s. Three 10-min animations (flying duck, roller coaster ride, and moving ball) will be shown to the subject during each EEG-NFB training session. The raw EEG signal, TBR value over time, EEG signal noise, and EEG theta and beta wave amplitudes will be recorded.
Study NCT00811642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: 400mg BID oral suspension for 12 weeks
Study NCT02306031 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prescribe ARTIFICIAL TEAR
Description: From one week before surgery, and control group received artificial tear (Sina Darou Laboratories Company, Tehran, Iran) as a placebo every 6 hours. Theses drops continued up to 6 weeks with the same dose after operations
Study NCT02306031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prescribe diclofenac sodium drop 0.1%
Description: From one week before surgery, case group received diclofenac sodium drop 0.1% (Sina Darou Laboratories Company, Tehran, Iran) every 6 hours.Theses drops continued up to 6 weeks with the same dose after operations
Study NCT02727530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VISCERAL MANUAL THERAPY-ADVICES
Description: The subjects of this group will receive an amount of two sessions of visceral manual therapy that will be applied within two weeks. In the first session will be applied procedures in the most superficial body structures. And, in the second session will be applied procedures in the most deep body structures.
Study NCT02727530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADVICES
Description: Advices for parents to improve the management of infant colic
Study NCT03978143 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Treatment A
Description: Single 250 mg crizotinib dose as coated microsphere 1 (cMS1) formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
Study NCT03978143 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Treatment B
Description: A single 250 mg crizotinib dose as coated microsphere 2 (cMS2) formulation will be administered on the morning of Day 1 after overnight fast of at least 10 hours.
Study NCT03978143 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Treatment C
Description: A single 250 mg crizotinib dose as FC formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
Study NCT03978143 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Treatment D
Description: A single 250 mg crizotinib dose as OS will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
Study NCT03978143 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Treatment E
Description: 250 mg crizotinib as cMS1 formulation will be administered with high-fat, high-calorie meal after an overnight fast of at least 10 hours.
Study NCT03978143 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Treatment F
Description: 250 mg crizotinib as cMS2 will be administered with a high-fat, high-calorie meal after an overnight fast of at least 10 hours.
Study NCT03978143 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Treatment G
Description: 40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS1 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
Study NCT03978143 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Treatment H
Description: 40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS2 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
Study NCT02310087 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: astaxanthin with vitamin E
Description: Four tablets of 4 mg astaxanthin with 10 mg vitamin E daily, taken at once. Daily dose is 16 mg astaxanthin with 40 mg vitamin E. Continuously for three months.
Study NCT02310087 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four tablets of placebo daily, taken at once. Continuously for three months.
Study NCT02867553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT02867553 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Multi-fields radiotherapy
Study NCT01167387 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PREOP
Description: a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrine; 240 mOsm/L) in dose of 800 mL
Study NCT01167387 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: water
Description: The control group will receive plain water with the same volume and timing of treatment.
Study NCT03048136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT03048136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT00934102 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon A contact lens
Description: Commercially marketed, silicone hydrogel, spherical soft contact lens
Study NCT00934102 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Galyfilcon A contact lens
Description: Commercially marketed, silicone hydrogel, spherical soft contact lens
Study NCT02304926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: simvastatin (40 mg/day) for 4 weeks
Study NCT02304926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: ezetimibe (10 mg/day) for 4 weeks
Study NCT02304926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin + Ezetimibe
Description: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period
Study NCT02673255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus and Diphtheria (Td) Vaccine
Study NCT05651347 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, visually identical to the melatonin tablets, but containing no active ingredient are administered three times a day.
Study NCT05651347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 10 MG
Description: Melatonin 10 mg tablets will be administered three times a day, up to a maximum of 30 mg daily
Study NCT01510327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROMUS Element Everolimus-Eluting Coronary Stent System
Description: PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
Study NCT01510327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
Study NCT01510327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thienopyridine
Description: Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
Study NCT00801814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX (PGX)
Description: 2.5 grams of PGX
Study NCT00801814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX (PG)
Description: 5.0 grams of PGX
Study NCT00621621 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Freezor® Cardiac Cryoablation Catheter CryoConsole System
Description: cryoablation
Study NCT00621621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freezor® Cardiac Cryoablation Catheter CryoConsole System
Description: cryoablation
Study NCT02153879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: fenofibrate 145/day for 12 weeks
Study NCT02153879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin plus laropiprant
Description: Niacin 2 g/day plus Laropiprant for 12 weeks
Study NCT00801814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX
Description: 7.5 grams of PGX
Study NCT00801814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 0g of PGX
Study NCT01306578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIG
Description: Intravenous Immune Globulin at a dose 0f 0.4 g/kg/day for 5 consecutive days
Study NCT01306578 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasma Exchange
Description: Five sessions of plasma exchange, single plasma volume each, for 5 consecutive days
Study NCT04416230 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: quiet time
Description: During quiet time, the infant received a 30 minute quiet time (QT) period during which non-essential caregiving tasks were restricted. During QT, clinicians were asked to avoid direct clinical caregiving activities, i.e. activities requiring physical contact with the infant.
Study NCT03093688 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of iNKT cells and CD8+T cells
Description: The eligible patients receive twice infusions of iNKT cells(1E8\~1E10) and CD8+T cells(1E7\~1E9) in one course of treatment.
Study NCT04738305 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dignity Therapy
Description: The Italian version Dignity Therapy intervention (Chochinov HM 2015) has been delivered. Intervention questions were not previously delivered to patients.~DT interview was provided to patients by Specifically trained Nurses. Interviews were audio-recorded and transcribed then revised by the patients to develop the final Generativity Document. Generativity Document was delivered to patients that could share it with their loved ones.
Study NCT01829243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Study NCT01829243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Milnacipran
Study NCT01829243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01829243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03206164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asynchronous, eLearning Intervention
Description: 20 CBOs with 3-member team (n= 30) will be recruited and placed into either the experimental or the comparison group.